- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Video
Dermatology Times Chief Medical Editor Weighs in On Black Box Warning for JAK Inhibitors
Author(s):
In this exclusive video interview, Zoe Diana Draelos, MD, Dermatology Times chief medical editor, weighs in on the recent Black Box Warning issued by the FDA to certain JAK inhibitors.
Video Player is loading.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Addressing Ongoing Benzoyl Peroxide and Benzene Updates at AAD 2025
Expert Insights Into L'Oréal’s Voluntary Recall of Benzoyl Peroxide Products
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Topical Corticosteroids: Potency, Vehicles, and Best Practices
Bunick Highlights Efficacy and Safety of JAK Inhibitors
FDA Approves Dupliumab for Prurigo Nodularis
Timber Pharmaceuticals Presents CI Study Data at EADV Congress
Stephen Stripling, MD, FAAP, Discusses Study of Berdazimer Gel for Molluscum Contagiosum
How Infusion Centers Support Dermatology Research
What's Happening in the Vitiligo Pipeline?
Related Content
